17 related articles for article (PubMed ID: 31622213)
1. The Effects of G2013 (α-L-guluronic Acid) in a Pentylenetetrazole-induced Kindling Animal Model of Epilepsy.
Tahmasebi S; Azizi G; Miladi H; Shafiei E; Kamali AN; Hamedifar H; Fayyaz F; Rasouli SE; Kalvandi M; Mohammadi H; Hassannia H; Eslami S; Hamid KM; Mirshafiey A
Innov Clin Neurosci; 2020 Apr; 17(4-6):9-12. PubMed ID: 32802585
[No Abstract] [Full Text] [Related]
2. The Open, Randomized, Positive Control Clinical Trial of Guluronic Acid (G2013) on SARS-CoV-2 Patients.
Aghazadeh Z; Sanaee Delir D; Gholamrezaie HR; Sadoughi A; Nezami Asl A; Noori Sanami M; Mahdavi Gorabi A; Panahi Y; Taeb M; Razavi A; Rafia S; Naderiyan Z; Robat-Jazi B; Mirshafiey A
Curr Drug Discov Technol; 2023; 20(4):e180423215957. PubMed ID: 37076459
[TBL] [Abstract][Full Text] [Related]
3. Dysregulated miRNAs network in the critical COVID-19: An important clue for uncontrolled immunothrombosis/thromboinflammation.
Mortazavi-Jahromi SS; Aslani M
Int Immunopharmacol; 2022 Sep; 110():109040. PubMed ID: 35839566
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotective effect of β-d-mannuronic acid (M2000) as a novel NSAID on gene expression of oxLDL scavenger receptors in the experimental diabetic model.
Mortazavi-Jahromi SS; Alizadeh S; Javanbakht MH; Mirshafiey A
Immunopharmacol Immunotoxicol; 2018 Aug; 40(4):284-289. PubMed ID: 29619884
[TBL] [Abstract][Full Text] [Related]
5. Assessment of immunological profile in ankylosing spondylitis patients following a clinical trial with guluronic acid (G2013), as a new NSAID with immunomodulatory properties.
Mortazavi-Jahromi SS; Nazeri S; Jafarnezhad-Ansariha F; Oraei M; Mirshafiey A
Immunol Res; 2019 Feb; 67(1):108-115. PubMed ID: 30474833
[TBL] [Abstract][Full Text] [Related]
6. Effect of Guluronic Acid (G2013), As a New Anti-inflammatory Drug on Gene Expression of Pro-inflammatory and Anti-inflammatory Cytokines and Their Transcription Factors in Rheumatoid Arthritis Patients.
Bakhtiari T; Azarian S; Ghaderi A; Ahmadzadeh A; Mirshafiey A
Iran J Allergy Asthma Immunol; 2019 Nov; 18(6):639-648. PubMed ID: 32245307
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Effect of α-L-Guluronic Acid (G2013) on COX-1, COX-2 Activity and Gene Expression for Introducing this Drug as a Novel NSAID with Immunomodulatory Property.
Mirshafiey A; Mortazavi-Jahromi SS; Taeb M; Cuzzocrea S; Esposito E
Recent Pat Inflamm Allergy Drug Discov; 2018; 12(2):162-168. PubMed ID: 29879894
[TBL] [Abstract][Full Text] [Related]
8. Anti-diabetic effect of
Mortazavi-Jahromi SS; Alizadeh S; Javanbakht MH; Mirshafiey A
Arch Physiol Biochem; 2019 Dec; 125(5):435-440. PubMed ID: 29882437
[TBL] [Abstract][Full Text] [Related]
9. Anti-Diabetic and Angio-Protective Effect of Guluronic Acid (G2013) as a New Nonsteroidal Anti-Inflammatory Drug in the Experimental Model of Diabetes.
Mortazavi-Jahromi SS; Alizadeh S; Javanbakht MH; Mirshafiey A
Endocr Metab Immune Disord Drug Targets; 2020; 20(3):446-452. PubMed ID: 31622213
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
